Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor

Molecular and Cellular Biology

Volumn 28, Issue 1, 2008, Pages 302-314

  Khacho, Mireille ^a   Mekhail, Karim ^a,b   Pilon Larose, Karine ^a   Payette, Josianne ^a   Lee, Stephen ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; DACTINOMYCIN; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; POLYADENYLIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOLECULAR DYNAMICS; NONHUMAN; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN TRANSPORT; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; NUCLEAR EXPORT SIGNALS; OXYGEN; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 37549042839     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01044-07     Document Type: Article

References (62)

1. Afonina, E., R. Stauber, and G. N. Pavlakis. 1998. The human poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm. J. Biol. Chem. 273:13015-13021.
2. Blondel, M., J. M. Galan, Y. Chi, C. Lafourcade, C. Longaretti, R. J. Deshaies, and M. Peter. 2000. Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. EMBO J. 19:6085-6097.
3. Bogerd, H. P., R. A. Fridell, R. E. Benson, J. Hua, and B. R. Cullen. 1996. Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol. Cell. Biol. 16:4207-4214.
4. Bonicalzi, M. E., I. Groulx, N. de Paulsen, and S. Lee. 2001. Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 276:1407-1416.
5. Bruick, R. K., and S. L. McKnight. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340.
6. Chen, F., T. Kishida, M. Yao, T. Hustad, D. Glavac, M. Dean, J. R. Gnarra, M. L. Orcutt, F. M. Duh, G. Glenn, et al. 1995. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5:66-75.
7. Cockman, M. E., N. Masson, D. R. Mole, P. Jaakkola, G. W. Chang, S. C. Clifford, E. R. Maher, C. W. Pugh, P. J. Ratcliffe, and P. H. Maxwell. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:25733-25741.
8. Epstein, A. C., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield, and P. J. Ratcliffe. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54.
9. Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj, and R. Luhrmann. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82:475-483.
10. Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051-1060.
11. Franovic, A., I. Robert, K. Smith, G. Kurban, A. Pause, L. Gunaratnam, and S. Lee. 2006. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 66:8083-8090.
12. Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288-7293.
13. Fukuchi, M., T. Imamura, T. Chiba, T. Ebisawa, M. Kawabata, K. Tanaka, and K. Miyazono. 2001. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol. Biol. Cell 12: 1431-1443.
14. Fukuda, M., S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and E. Nishida. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390:308-311.
15. Gallou, C., D. Chauveau, S. Richard, D. Joly, S. Giraud, S. Olschwang, N. Martin, C. Saquet, Y. Chretien, A. Mejean, J. M. Correas, G. Benoit, P. Colombeau, J. P. Grunfeld, C. Junien, and C. Beroud. 2004. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum. Mutat. 24:215-224.
16. Groulx, I., M. E. Bonicalzi, and S. Lee. 2000. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J. Biol. Chem. 275:8991- 9000.
17. Groulx, I., and S. Lee. 2002. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22:5319-5336.
18. Gunaratnam, L., M. Morley, A. Franovic, N. de Paulsen, K. Mekhail, D. A. Parolin, E. Nakamura, I. A. Lorimer, and S. Lee. 2003. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278:44966-44974.
19. Hansen, W. J., M. Ohh, J. Moslehi, K. Kondo, W. G. Kaelin, and W. J. Welch. 2002. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22:1947-1960.
20. Harris, A. L. 2002. Hypoxia: a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47.
21. Henderson, B. R., and A. Eleftheriou. 2000. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp. Cell. Res. 256:213-224.
22. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-479.
23. Ivan, M., and W. G. Kaelin, Jr. 2001. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:27-34.
24. 2 sensing. Science 292:464-468.
25. Iwai, K., K. Yamanaka, T. Kamura, N. Minato, R. C. Conaway, J. W. Conaway, R. D. Klausner, and A. Pause. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 96:12436-12441.
26. 2-regulated prolyl hydroxylation. Science 292:468-472.
27. Kaelin, W. G., Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2:673-682.
28. Kaelin, W. G., Jr., and E. R. Maher. 1998. The VHL tumour-suppressor gene paradigm. Trends Genet. 14:423-426.
29. Kalderon, D., B. L. Roberts, W. D. Richardson, and A. E. Smith. 1984. A short amino acid sequence able to specify nuclear location. Cell 39:499-509.
30. Kibel, A., O. Iliopoulos, J. A. DeCaprio, and W. G. Kaelin, Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444-1446.
31. Kudo, N., N. Matsumori, H. Taoka, D. Fujiwara, E. P. Schreiner, B. Wolff, M. Yoshida, and S. Horinouchi. 1999. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96:9112-9117.
32. Kutay, U., and S. Guttinger. 2005. Leucine-rich nuclear-export signals: born to be weak. Trends Cell. Biol. 15:121-124.
33. Latif, F., K. Tory, J. Gnarra, M. Yao, F. M. Duh, M. L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
34. Lee, S., M. Neumann, R. Stearman, R. Stauber, A. Pause, G. N. Pavlakis, and R. D. Klausner. 1999. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19:1486-1497.
35. Leroux, M. R., and F. U. Hartl. 2000. Protein folding: versatility of the cytosolic chaperonin TRiC/CCT. Curr. Biol. 10:R260-R264.
36. Li, L., L. Zhang, X. Zhang, Q. Yan, Y. A. Minamishima, A. F. Olumi, M. Mao, S. Bartz, and W. G. Kaelin, Jr. 2007. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2a and type 2b Vhl mutations. Mol. Cell. Biol. 27:5381-5392.
37. Lindstrom, M. S., A. Jin, C. Deisenroth, G. White Wolf, and Y. Zhang. 2007. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 27:1056-1068.
38. Lisztwan, J., G. Imbert, C. Wirbelauer, M. Gstaiger, and W. Krek. 1999. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1822-1833.
39. Lonergan, K. M., O. Iliopoulos, M. Ohh, T. Kamura, R. C. Conaway, J. W. Conaway, and W. G. Kaelin, Jr. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18:732-741.
40. Maher, E. R., and W. G. Kaelin, Jr. 1997. von Hippel-Lindau disease. Medicine (Baltimore) 76:381-391.
41. Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
42. Mekhail, K., L. Gunaratnam, M. E. Bonicalzi, and S. Lee. 2004. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 6:642-647.
43. Mekhail, K., M. Khacho, A. Carrigan, R. R. Hache, L. Gunaratnam, and S. Lee. 2005. Regulation of ubiquitin ligase dynamics by the nucleolus. J. Cell Biol. 170:733-744.
44. +: implications for HIF and hypoxic cell memory. Cell Cycle 3:1027-1029.
45. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
46. Ohh, M., C. W. Park, M. Ivan, M. A. Hoffman, T.-Y. Kim, L. E. Huang, N. Pavletich, V. Chau, and W. G. Kaelin. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the [bgr]-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:423-427.
47. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
48. Pastore, Y., K. Jedlickova, Y. Guan, E. Liu, J. Fahner, H. Hasle, J. F. Prchal, and J. T. Prchal. 2003. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am. J. Hum. Genet. 73:412-419.
49. Pastore, Y. D., J. Jelinek, S. Ang, Y. Guan, E. Liu, K. Jedlickova, L. Krishnamurti, and J. T. Prchal. 2003. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101:1591-1595.
50. Pause, A., S. Lee, R. A. Worrell, D. Y. Chen, W. H. Burgess, W. M. Linehan, and R. D. Klausner. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94:2156-2161.
51. Phair, R. D., and T. Misteli. 2000. High mobility of proteins in the mammalian cell nucleus. Nature 404:604-609.
52. Rasmussen, A., S. Nava-Salazar, P. Yescas, E. Alonso, R. Revuelta, I. Ortiz, S. Canizales-Quinteros, M. T. Tusie-Luna, and M. Lopez-Lopez. 2006. Von Hippel-Lindau disease gcrmline mutations in Mexican patients with cerebellar hemangioblastoma. J. Neurosurg. 104:389-394.
53. Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554-564.
54. Scheffner, M. 1999. Moving protein heads for breakdown. Nature 398:103-104.
55. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721-732.
56. Smith, K., L. Gunaratnam, M. Morley, A. Franovic, K. Mekhail, and S. Lee. 2005. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 65:5221-5230.
57. Stade, K., C. S. Ford, C. Guthrie, and K. Weis. 1997. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90:1041-1050.
58. Kip1 is instigated by Jabl. Nature 398:160-165.
59. Weissman, A. M. 2001. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:169-178.
60. Wen, W., J. L. Meinkoth, R. Y. Tsien, and S. S. Taylor. 1995. Identification of a signal for rapid export of proteins from the nucleus. Cell 82:463-473.
61. Whaley, J. M., J. Naglich, L. Gelbert, Y. E. Hsia, J. M. Lamiell, J. S. Green, D. Collins, H. P. Neumann, J. Laidlaw, F. P. Li, et al. 1994. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55:1092-1102.
62. Yu, F., S. B. White, Q. Zhao, and F. S. Lee. 2001. HIF-lalpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98:9630-9635.